Christopher Pierce serves as Executive at Prelude Therapeutics Inc, where they oversee executive responsibilities. Since joining the company, Christopher Pierce has executed 11 insider transactions totaling $953.7K, demonstrating a bearish approach to their equity position. Their most recent transaction on Sep 2, 2021 involved selling 6,930 shares valued at $294.5K.
Christopher Pierce currently holds 3,750 shares of Prelude Therapeutics Inc (PRLD), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Pierce has been a net seller of PRLD stock. They have purchased $71.3K and sold $882.5K worth of shares.
Christopher Pierce's most recent insider trade was on Sep 2, 2021, when they sold 6,930 shares at $42.50 per share.
Get notified when new Form 4 filings are submitted
| $12.85 |
| Discretionary |
| Sep 2, 2021 | PRLD | $134.7K | Sale | 3,343 | $40.29 | Discretionary |
| Sep 2, 2021 | PRLD | $279.3K | Sale | 6,727 | $41.52 | Discretionary |
| Apr 29, 2021 | PRLD | $132.8K | Sale | 3,295 | $40.29 | Discretionary |
| Apr 29, 2021 | PRLD | $6.2K | Option Exercise | 3,295 | $1.89 | Discretionary |
| Apr 8, 2021 | PRLD | $8.0K | Sale | 200 | $40.00 | Discretionary |
| Apr 8, 2021 | PRLD | $378 | Award | 200 | $1.89 | Discretionary |
| Apr 7, 2021 | PRLD | $33.2K | Sale | 828 | $40.08 | Discretionary |
| Apr 7, 2021 | PRLD | $1.6K | Award | 828 | $1.89 | Discretionary |
| Sep 29, 2020 | PRLD | $71.3K | Purchase | 3,750 | $19.00 | Discretionary |